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Abstract
Background:  Endoscopic resectional techniques for colon cancer are undermined by their
inability to determine lymph node status. This limits their application to only those lesions at the
most minimal risk of lymphatic dissemination whereas their technical capacity could allow
intraluminal or even transluminal address of larger lesions. Sentinel node biopsy may theoretically
address this breach although the variability of its reported results for this disease is worrisome.
Methods: Medline, EMBASE and Cochrane databases were interrogated back to 1999 to identify
all publications concerning lymphatic mapping for colon cancer with reference cross-checking for
completeness. All reports were examined from the perspective of in vivo technique accuracy
selectively in early stage disease (i.e. lesions potentially within the technical capacity of endoscopic
resection).
Results: Fifty-two studies detailing the experiences of 3390 patients were identified. Considerable
variation in patient characteristics as well as in surgical and histological quality assurances were
however evident among the studies identified. In addition, considerable contamination of the
studies by inclusion of rectal cancer without subgroup separation was frequent. Indeed such is the
heterogeneity of the publications to date, formal meta-analysis to pool patient cohorts in order to
definitively ascertain technique accuracy in those with T1 and/or T2 cancer is not possible.
Although lymphatic mapping in early stage neoplasia alone has rarely been specifically studied, those
studies that included examination of false negative rates identified high T3/4 patient proportions
and larger tumor size as being important confounders. Under selected circumstances however the
technique seems to perform sufficiently reliably to allow it prompt consideration of its use to tailor
operative extent.
Conclusion: The specific question of whether sentinel node biopsy can augment the oncological
propriety for endoscopic resective techniques (including Natural Orifice Transluminal Endoscopic
Surgery [NOTES]) cannot be definitively answered at present. Study heterogeneity may account
for the variability evident in the results from different centers. Enhanced capacity (perhaps to the
level necessary to consider selective avoidance of en bloc mesenteric resection) by its confinement
to only early stage disease is plausible although not proven. Specific study of the technique in early
stage tumors is clearly essential before proffering this approach.
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Background
Advances in technological capability have made feasible
the local resection of small colonic tumors by intralumi-
nal and even transluminal endoscopy [1-4]. Although pri-
marily now proposed for supposed benign lesions, in
concept, selected germinal cancers could also be resected
by these means. However, the insensitivity of preoperative
radiological imaging for the detection of nodal metastases
(approximately 70% of tumor-containing nodes are less
than 5 mm in size [5-9]) and the inability of biopsy anal-
ysis to truly reflect the metastatic potential of the primary
means that localized resection of the primary for even the
earliest cancers risks either the understaging of systemic
disease or the rendering of the effort redundant if formal
resection becomes indicated by the full pathology of the
resected specimen[10]. A reliable means of definitively
establishing lymph node status peroperatively, other than
en bloc mesenteric resection, would greatly increase the
oncological providence of these techniques and could
expand their application.
Sentinel node biopsy would seem on first principles well
suited to address this breach as it fulfills a similar role in
tumors of the breast and skin. This technique has also
been recently proposed to accompany endoscopic dissec-
tion of early gastric cancers in order to enhance functional
outcome by minimizing the extent of surgical resection
[11-13]. Adjoining such a 'diagnostic laparoscopy' to an
endoscopic resective technique could be justified in
selected patients if the outcome of the node biopsy would
permit localized excision as the definitive intervention in
place of radical operation. Conversely, if the node is
revealed as positive for metastases, the surgeon can confi-
dently advocate radical operation in cases when the tumor
appears confined. Synchronous laparoscopy has indeed
already been advocated for the endoscopic resection of
certain difficult or large polyps[14]. Furthermore, it seems
likely that increasing experience with transluminal perito-
neal access and intervention (i.e. Natural Orifice Translu-
minal Endoscopic Surgery [NOTES]) could mean that
selective lymph node biopsy without abdominal wall
ingress will be practicable in the near future[15]. How-
ever, lymphatic mapping in intestinal cancers is still con-
sidered controversial because of reports of varying
accuracy and concerns regarding reliability and reproduc-
ibility.
To date however no comprehensive study or review has
been performed from the perspective of using lymphatic
mapping to facilitate minimally resective techniques for
early stage colon tumors. Analyses to date have instead
focused primarily on the capacity of the technique to pre-
dict recurrence risk through the upstaging of convention-
ally node negative disease after standard operation has
been performed [16-24]. The main focus has therefore
been on Stage II rather than Stage I cancers with the senti-
nel node biopsy and analysis being performed in addition
to rather than in place of formal lymphadenectomy[25].
The aim of this review is therefore to formally interrogate
the evidence base in its entirety to determine whether
lymphatic mapping can, on any basis, be rationally pro-
posed to augment the oncological propriety of localized
endoscopic resection specifically for the small, early stage
colon cancers that lie within its scope.
Note: Rectal cancers lie outside the premise of this review
as the anatomical arrangement of the mesorectum (specif-
ically its bulk, retroperitoneal position and lack of serosal
layer) precludes against intraoperative nodal biopsy for
rectal cancer. Furthermore, violation of the mesorectum
may also compromise any subsequent attempt at formal
oncological resection (and hence negatively impact upon
patient outcome) should this be indicated by the pathol-
ogy of the resected specimen.
Methods
Search methods for identification of relevant studies
The following strategy was used to identify relevant publi-
cations regarding experience with lymphatic mapping in
human patients with colon cancer (see Table 1). Firstly,
PubMed software was used to search the Medline database
between 1st January 1999 (the year of the earliest series
published on the technique in colon cancer) and the 30th
July 2008. The Cochrane library (including the Cochrane
Central Register of Controlled Trials) and EMBASE data-
bases were also directly searched in a similar fashion. The
following expanded Medical Subject Headings were used-
'sentinel node', 'lymphatic mapping', 'colon cancer',
'colon tumo(u)rs', 'colorectal cancer/tumo(u)rs', 'large
intestine' and 'gastrointestinal' (although the intent of the
study was confined to colon cancer the later three search
terms were included for completeness as some series
report mixed cohorts). The reference list of all full publi-
cations so identified along with that of consensus papers,
review articles, editorials and relevant book chapters were
cross-checked for additional relevant publications. Data
contained in meeting abstracts were not studied as these
were judged unlikely to present sufficient detail for extrac-
tion required by our study protocol. Only English lan-
guage publications were included (language bias however
seems unlikely since the literature search in Pubmed and
Table 1: Inclusion criteria for inclusion of publication in this 
review.
Inclusion criteria
English language publication
Full publication between 1st January 1999 and July 30th 2008.
Human patients with colon cancer
In vivo mapping and node identificationBMC Surgery 2008, 8:17 http://www.biomedcentral.com/1471-2482/8/17
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Embase did not reveal any substantial non-english
reports). Finally only those studies that used vivo method-
ology alone for both the injection and the identification
of salient sentinel nodes were analyzed (ex vivo mapping
can only be reliably performed if a specimen with its com-
plete mesentery has already been resected intact while ex
vivo identification can predispose to false negative glands
as redistribution of the dye along the lymphatic chain can
occur in the time between injection and node harvest).
Intraoperative marking of the sentinel node rather than
actual excisional biopsy allowed inclusion however as
clearly the intent and purpose is the same.
Assessment of methodological quality of the studies 
identified
Each of the studies identified was analyzed for suitability
for inclusion according to the criteria laid down by QUA-
DRAS – an evidenced base tool for the assessment of the
quality of diagnostic assessment studies[26,27]. By this
means it was determined whether the publication was of
sufficient quality to allow inclusion in this review.
Data extraction from included studies
All data extraction was performed by two authors (RAC
and JL) with cross-checking to ensure validation. When
any disparity or disagreements arose the investigators met
with the third author JM as final adjudicator to resolve the
debate. The fields for data capture were pre-specified
before analysis of the studies identified. Data pertaining
to patient demographics, technique methodology
(including both surgeon experience as well as precise tech-
nical details) and sentinel node efficacy by binary classifi-
cation (i.e. detection, accuracy, sensitivity and false
negative rates as well as negative predictive values) for
patients with colon cancer undergoing lymphatic map-
ping were prepared on Microsoft Excel datasheets. Data
from papers that explicitly declared themselves further
sub-analyses of a previous study were included with the
prior publication. Studies from the same authors but
which did not declare themselves to contain overlapping
cohorts were analyzed separately although are flagged in
the subsequent tables to indicate that this is possibility.
When quantitative results were not presented and were
not extractable only that data that was useful to this anal-
ysis was extracted (data not presented and impossible to
extract is denoted in the tables by ns (i.e. 'not stated').
Otherwise the paper was excluded. In cases of mixed pop-
ulations, where possible, only data relating to the in vivo
mapping and biopsy of sentinel nodes in colon cancer
were extracted. If not possible, the data was included with
note made of the circumstances. Finally any further for-
mal results analyses or additional hard data (rather than
speculative commentary or theoretical opinion) from the
Methods, Results or Discussions sections of the studies
was also recorded to allow for subsequent analysis and
consideration.
Sentinel Node Performance Parameters
Where possible, 2 × 2 contingency tables were built com-
prising true positive (both sentinel and non-sentinel
nodes involved), true negative (both sentinel and non-
sentinel nodes clear), false negative (sentinel node clear
but non-sentinel nodes involved). The term 'false positive'
(and hence calculation of 'specificity') is not appropriate
in studies regarding sentinel node in cancer because the
presence of isolated macrometastases in the sentinel node
confers node positivity on the patient. Nor, given the
experimental nature of sentinel node biopsy and the bio-
logical uncertainty of the significance of micrometastases,
is this term appropriate for use when micrometastases
alone are present in the sentinel node. Instead the term
upstaging is used to better reflect the standing of sentinel
nodes that are immunohistochemically positive when
other non-sentinel nodes are clear of disease.
The following definitions were therefore used to ascribe
the performance rates of sentinel node biopsy
Detection rate – refers to the number of times a sentinel
node was actually identifiable = (Number of successful
attempts to retrieve a sentinel node/Number of attempts
to retrieve a sentinel node)*100%.
Accuracy rate refers to the ability of the sentinel node to
reflect the overall status of the lymph basin (whether pos-
itive or negative) = [(Number of correct predictions of the
nodal status by sentinel node biopsy/Number of patients
undergoing sentinel node biopsy)*100%].
Sensitivity refers to the number of times the sentinel node
reflects the fact that disease is present in the non-sentinel
nodes = (Number of patients with tumor-involved senti-
nel nodes/Number of patients with any lymph node con-
taining tumor)*100%.
The false negative rate reflects the proportion of patients
in whom no cancer was identified in the sentinel node but
who had nodal deposits found in their non-sentinel
nodes compared to the total number of those who had
tumour containing metastases in non-sentinel nodes =
(Number of false negative patients/Number of true posi-
tive cases + number of false-negative cases) *100%.
Upstaging rate refers to the number of cases in which
sophisticated analysis of the sentinel node reveals tumor
deposits that otherwise would not have been detected =
(Number of patients revealing micrometastases or iso-
lated tumor cells in the sentinel node/Number of patientsBMC Surgery 2008, 8:17 http://www.biomedcentral.com/1471-2482/8/17
Page 4 of 20
(page number not for citation purposes)
classified as N0 after routine histopathological examina-
tion)*100%.
Results
Results of literature search
There were no randomized controlled trails identified by
our search methodology. Sixty-three clinical studies
regarding lymphatic mapping and sentinel node biopsy
for colon cancer in human patients were published in the
English language during our review period of interest.
Nine of these studies however actually utilized a primarily
ex vivo lymph node identification technique (only the dye
injection was performed in vivo and the surgeon made no
attempt intraoperatively to identify any mapped nodes).
These studies [28-37](along with ten additional studies
that utilized a primary ex vivo technique ab initio [38-
46]) were therefore excluded from further analysis (see
Figure 1 and Table 2). A further two studies were explicitly
declared updates or further analyses of already reported
patient cohorts.
This left fifty-two studies warranting consideration for
inclusion in this study [21,47-97](see Table 3). Although
ten of these studies supplemented their in vivo work with
additional ex vivo examination on a occasional basis (par-
ticularly in cases of failed mappings or rectal cancers),
these were included in the review as their majority of cases
underwent their mapping and biopsy entirely in vivo
prior to specimen resection. In addition, aside from any
contribution to multicenter trials, seven centers provided
27 studies to the literature base. Eight publications have
come from the John Wayne Cancer Institute alone and
seven have come from the McLaren Regional Center,
Michigan State University alone (with a further four pub-
lications emerging from these two centers jointly). Two
centers (Wake Forest, North Carolina and MD Anderson,
Texas) have published two studies each while three cent-
ers (Mount Sinai, Miami Beach; Charité-University Medi-
cine Berlin, Germany and the University Medical Center
Groningen, Netherlands) have published two studies
each. However, although some degree of overlap between
patient cohorts is likely in successive publications that
exact proportion of patients presented in duplicate was
Flow chart showing the selection and exclusion of publications for this review Figure 1
Flow chart showing the selection and exclusion of publications for this review.BMC Surgery 2008, 8:17 http://www.biomedcentral.com/1471-2482/8/17
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not explicitly stated and so all studies were included albeit
with flagging.
Included studies
In total fifty two diagnostic studies (listed in Table 3)
detailing 3390 patient episodes were included in this
analysis. Only two studies (comprising a total of 41
patients)[52,91] however set out specifically to evaluate
lymphatic mapping selectively for early stage disease. This
obviously is not a sufficient cohort to draw robust conclu-
sions about the performance of the technique in this
cohort. The clinical and methodological diversity (com-
pounded by variations in data presentation) of the
remaining forty-eight studies however was such that for-
mal meta-analysis to allow statistical analysis supplement
the power was neither possible nor prudent (QUADROS
data not shown). Therefore this systematic review of the
literature on this subject must take the form of a narrative
synthesis of the evidence base in its entirety[98].
Sentinel node detection rates and false negative scores are
listed alongside each publication in Table 3 and displayed
graphically in Figure 2. As can be seen considerable varia-
tion in both detection rates (58–100%) and, especially, in
false negative rates (0–75%) is evident. To be of any clin-
ical utility the technique would seem to require these rates
to be consistently better than 90% and 10% respectively
(i.e. similar to that deemed acceptable for clinical use of
the technique in breast cancer). Forty-five studies present
identification rates greater than this threshold (indeed 34
had rates greater than 95% while twelve identified senti-
nel nodes in 100% of their patients). Twenty studies
reported a false negative rate of 10% or below (although
eight of these studies have been published from the two
centers with the most publications) and eight studies
reported a false negative rate of less than 5%. While these
data suggest that the technique could be apposite for the
determination of operative extent, the eight and thirty
studies (16% and 60% respectively of all the published
experience) that fail to demonstrate such levels of efficacy
raise considerable concern over its reliability and repro-
ducibility. However the same factors that preclude meta-
analysis (i.e. the considerable heterogeneity regarding var-
iable patient cohorts and tumor characteristics as well as
disparate surgeon experience and protocol differences in
both the technical performance and pathological analy-
sis) may also underlie these discordant results and will
now therefore be critically analyzed in sequence. Tables 4,
5 and 6 detail the salient findings of each study by each of
these criteria.
Patient Demographics (Table 4)
Ten studies gave no indication of mean (or median)
patient age while eleven gave no breakdown of the patient
population by gender. The age breakdown of the other
studies show no especially striking data (mean age 69
years) although three studies have an unexplained clear
preponderance (>70%) of males as have two of females
among their cohorts. This suggests that their populations
may be somewhat atypical. Only four studies present data
regarding the BMIs of their patient population – a poten-
tial important discrepancy that may induce error in both
detection and false negative rates as intra-abdominal
obesity may obscure discolored nodes in the mesentery.
Finally, only 25 (50%) studies examined colon cancer in
isolation. The vast majority (26) of the other studies also
included rectal cancer. These studies, despite usually
declaring the proportions of each tumor studied, most
often did not present result sub-analysis. While the mean
number of colon cancers studied in each publication is
68, 30 studies included less than 50 of such patients while
14 comprised less than 30 patients with colon cancer.
Tumor profiles (Table 5)
Despite the stated aim of most studies being the evalua-
tion of the utility of lymphatic mapping for staging node
negative tumors, 19 studies made no attempt to exclude
patients with distant metastases or indeed evident
Table 2: Studies excluded from analysis as primarily reports of ex vivo biopsy techniques.
Entirely ex vivo technique In vivo injection but ex vivo identification of mapped nodes
Lead Author Year Journal Lead Author Year Journal
Wong [28] 2001 Ann Surg Cserni [38] 1999 Path Oncol Res
Fitzgerald [29] 2002 J Surg Oncol Joosten [39] 1999 Br J Surg
Broderick-Villa [30] 2004 Am Surg Merrie [40] 2001 Dis Colon Rectum
Wong [31] 2004 Ann Surg Oncol Gandy [41] 2002 Colorectal Dis
Smith F [32] 2005 Ann Surg Oncol Evangelista [42] 2002 Tumori
Bell [33] 2005 Dis Col Rectum Demirbas [43] 2004 Turk J Gastroenterol
Smith J [34] 2006 Am J Surg Krishnan [44] 2005 Indian J Gastroenterol
Yagik [35] 2007 Int J Col Dis Van Scheltinga [45] 2006 Scand J Gastroenterol
Van Schaik [36] 2007 Eur J Surg Oncol Faerden AE [46] 2008 Dis Colon Rectum
Stojadinovic [37] 2007 Ann SurgBMC Surgery 2008, 8:17 http://www.biomedcentral.com/1471-2482/8/17
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Table 3: Publications included for this analysis along with their concluding results regarding the rates of detection, accuracy, 
sensitivity, false negative and upstaging as well as the false negative rates associated with lymphatic mapping and sentinel node biopsy 
for colon cancer. 
Lead Author Year Journal Detection 
Rate
Accuracy 
Rate
Sensitivity 
Rate
False Negative 
Rate
Negative 
Predictive 
Value
Upstaging 
Rate
Saha (a)[47] 2000 Ann Surg Oncol 99 96 91 9 Ns 18
Wiese (a)[48] 2000 Arch Pathol Lab Med 99 96 91 9 ns ns
Waters (b)[49] 2000 Am Surg 91 100 100 0 100 6
Bilchik (c)[50] 2001 J Clin Oncol 100 100 100 0 100 50
Paramo (d)[51] 2001 Am J Surg 71 100 100 0 100 11
Wood (a)+(c)[52] 2001 Ann Surg Oncol 96 95 88 12 ns 25
Wood (c)[53] 2001 Surg Endosc 100 100 100 0 100 9
Saha (a)+(c)[54] 2001 Ann Surg Oncol 98 96 90 10 95 14
Esser [55] 2001 Dis Colon Rectum 58 94 67 33 94 7
Bendavid [56] 2002 J Surg Oncol 90 94 95 5 91 42
Paramo (d)[57] 2002 Ann Surg Oncol 82 98 93 7 97 11
Wood (c)[58] 2002 J GastroInt Surg 97 95 92 8 ns 24
Bilchik (c)[59] 2002 Eur J Cancer 97 95 91 5 ns 24
Kitagawa [60] 2002 Dis Colon Rectum 91 92 82 18 88 ns
Feig (e)[61] 2002 Am J Surg 98 79 38 62 76 8
Broderick-Villa [62]2 0 0 2 C a n c e r  J 9 2 7 9 5 0 5 0 7 3 0
Tsioulias (c)[63] 2002 Am Surg 100 93 67 33 ns 15
Nastro [64] 2002 Tumori 75 100 100 0 100 ns
Bilchik (c)[65] 2003 Cancer Control 100 93 91 9 ns 14
Cox [66] 2003 Curr Surg 100 100 100 0 100 29
Bilchik (c)[67] 2003 J Clin Oncol 96 96 92 8 ns 29
Turner (c)[68] 2003 Archives Path 82 92 87 13 ns 29
Trocha (a)+(c)[69] 2003 J GastroInt Surg 98 95 84 16 93 21
Veihl [70] 2003 World J Surg 87 78 50 22 71 11
Levine (b)[71] 2003 J GastroInt Surg 92 ns 50 ns 86 ns
Saha (a)[72] 2004 Dis Colon Rectum 99 ns 88 12 ns 13
Dan (a)[73] 2004 Arch Surg 99 96 86 16 ns 5
Braat [21] 2004 Eur J Surg Oncol 94 97 80 20 92 3
Bertoglio [74]2 0 0 4 J  S u r g  O n c o l 9 5 9 2 7 8 2 2 8 8 n s
Read [75] 2004 Dis Colon Rectum 79 97 25 75 ns 3
Patten (e)[76]2 0 0 4 C a n c e r 9 8 8 9 8 3 1 7 7 6 2 0
Bertagnolli [77] 2004 Ann Surg 92 80 46 54 75 0
Saha (a)[78] 2004 Ann Surg Oncol 100 95 84 16 93 5
Saha (a)[79] 2004 Semin Oncol 100 96 92 8 ns 13
Bembenek (f)[80] 2005 World J Surg 85 ns 92 8 95 26
Codnignola [81] 2005 JJ Clin Oncol 100 ns 72 28 70 37
Dahl [82] 2005 Eur J Surg Oncol 100 92 83 17 91 ns
Bilchik (a)+(c)[83] 2006 Arch Surg 100 95 88 12 ns 23
Tuech [84] 2006 Eur J Surg Oncol 97 94 91 9 ns ns
Saha (a)[85] 2006 Am J Surg 98 96 90 10 93 ns
Kelder (g)[86] 2006 Scand J Gastroenterol 97 93 86 14 89 33
Thomas (b)[87] 2006 Am Surg 93 20 46 54 73 5
Covarelli [88] 2006 Am Surg 95 95 86 14 ns 8
Kelder (g)[89] 2007 Int J Col Dis 97 96 89 11 93 ns
Bianchi [90] 2007 Surg End 100 95 83 17 94 9
Murawa [91] 2007 Acta Chir Belg 93 84 83 17 ns 8
Bembenek (f)[92] 2007 Ann Surg 85 86 54 46 80 21
Sandrucci [93] 2007 J Surg Oncol 100 91 92 9 ns 11
Tiffet [94] 2007 Dis Colon Rectum 92 81 80 20 74 ns
Lim (e)[95] 2008 Ann Surg Oncol 99 83 59 41 78 ns
Kusano [96] 2008 Digestive Surgery 88.5 82.6 33 67 81 ns
Quadros [97]2 0 0 8 J  S u r g  O n c o l 9 1 8 0 6 7 3 3 6 7 2 5
The definitions for each are contained in the text. All rates are %; ns denotes data neither stated within nor readily derived from the results 
presented within the publication. Note: several centers have published more than one series without declaring overlap of their patient cohorts – 
such publications are flagged by the center of origin by the inclusion of letter subscript as follows: (a) McLaren Regional Center, Michigan, USA; (b) 
Wake Forest, North Carolina, USA; (c) John Wayne Cancer Institute, California, USA; (d) Mount Sinai, Miami Beach, USA; (e) MD Anderson, 
Texas; (f) Charité-University Medicine Berlin, Berlin, Germany; (g) University Medical Center Groningen, The Netherlands. Table 4,5 and 6 also 
follow a similar format.BMC Surgery 2008, 8:17 http://www.biomedcentral.com/1471-2482/8/17
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mesenteric deposits let alone grossly involved lymph
nodes. Indeed some actually specifically included such
patients. Of the remainder, seven excluded only patients
with distant metastases (making no further consideration
of local tumour invasion or mesenteric deposits) while
nine required the patient had only 'clinically localized' or
'resectable' disease to allow their inclusion. Of the twelve
papers that exclude gross nodal and distant metastases,
five include T4 disease while five do not profile their
tumors by T-stage. Overall, at least 21 studies include T4
tumors within their cohorts. Furthermore, 25 of the stud-
ies that present such data possess high T3 and T4 to T1
and T2 ratios. Only five studies specifically consider
tumor length or diameter as a factor that may affect per-
formance parameters. Interestingly, four of these studies
conclude that false negative rates are considerably more
likely in patients with larger tumors while the fifth only
examined this by taking 4 cm as a cut-off point for analy-
sis. Only one study considered how tumor size may relate
to the quantity of dye needed to adequately map it and
found a significant positive correlation. Although the
mean number of resected nodes in each study often is ade-
quate (mean overall is in 15.3), 21 studies include
patients who have had considerably less nodes than this
resected in their 'definitive' operation while 25 do not
state either the mean or range of the non-sentinel nodal
harvest. This raises concern over the quality control mech-
anisms in place to ensure the standard of the oncological
operation performed in these studies.
Technical methodology (Table 6)
Only five studies specifically sought to ensure surgeon
experience in the technique prior to commencing their
study (although an additional nine had already demon-
strated their competence in a prior publication). This is
likely particularly pertinent in the ten multicentre studies,
only four of whom specifically sought to ensure mini-
mum practical experience among their participants
(although a further three studies came from units that had
already published experiences and so this likely evinces
expertise at least among some of the contributors). Injec-
tion methodology overall was relatively similar. 45 proto-
cols utilized an intraoperative subserosal injection of
colorimetric mapping agent while three employed a sub-
mucosal injection. Twenty eight studies utilized isosulfan
blue 1% in isolation while ten used Patent Blue alone and
one used Vital Blue. Eight studies used a radioisotope as a
mapping agent (alone in one study and in conjunction
with blue dye in the others) and the majority injected this
agent submucosally preoperatively by additional endos-
copy. Two studies also incorporated fluorescein while one
used indocyanine green. Six studies specifically included
laparoscopic operations with three employing this
approach exclusively. All commenting authors agreed
however that the technique is easily performed regardless
of operative approach and adds minimally to overall
operative time[63]. The mean number of sentinel nodes
found was consistently approximately two although five
studies included within their range numbers in excess of
double this. There was though considerable variation
among how identified nodes were histologically ana-
lyzed. Four studies examined only a single section of the
sentinel node while nine used neither immunohisto-
chemistry nor RT-PCR to look for micrometastases or iso-
lated tumor cells (one of these did however subsequently
publish an additional, detailed report on their results with
such techniques[99]).
Despite the fact that the variation in accuracy and sensitiv-
ity rates is frequently decried, only fifteen publications
specifically included analysis of their false negative rates
(see Table 7 for a tabulated summary of their conclu-
sions). Twelve of these found that increasing tumor stage
was inversely related to non-sentinel node tumors and
indeed in five studies the detection rate and diagnostic
accuracy was 100% among their T1 and T2 cohorts. One
other study found that the presence of lymphovascular
invasion was significantly associated with false negative
rates but that lymph node invasion did not reach signifi-
cance as a predictor (no data was shown however). The
remaining study analyzing its results by tumor stage
found no significance difference with either tumor stage
or an arbitrarily decided lesion diameter.
Critical analysis of studies with low performance results
The nine studies with detection rates < 90% and the thirty-
two studies with false negative rates > 10% were then scru-
tinized from the perspectives gleaned from these analyses.
Interestingly, five of the nine studies (>50%) with low
detection rates also had false negative rates greater than
20% (actually 22%, 33%, 46% and 75%). Of the 43 stud-
ies with detection rates > 90%, only eleven (c. 25%) also
had false negative rates greater than 20%.
Of those with detection rates < 90%, two were multicen-
tric trials. Neither these nor six of the seven single centre
studies stated they validated surgeon expertise prior to
commencing patient enrollment. Furthermore each of
these studies was composed of less than 60 patients. Five
studies included a proportion of rectal cancers approxi-
mating 15% of the population within their study cohorts.
Four studies had marked T3/4 to T1/2 preponderance (in
the order of 93:3, 78:22 and 83:15 respectively). Only
three studies of those with detection rates > 90% included
such high proportions of locally advanced disease but one
of these specifically excluded clinically apparent lym-
phadenopathy while the other did not contain any T4
cases. Furthermore one other study included patients with
liver metastases and even obvious mesenteric deposits
and direct nodal invasion by the primary while everyBMC Surgery 2008, 8:17 http://www.biomedcentral.com/1471-2482/8/17
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patient in another study was conventionally node posi-
tive. Finally the patients of one report had a mean BMI
above 25 kg/m2 (although this was not analyzed specifi-
cally further). None of the other studies presented any
data in this latter regard.
Table 4: Cohort characteristics with regard to baseline demographics of the patients studied.
Lead Author % Males Mean or median age BMI
(kg/m2)
Non-colonic cancers 
included
% with colon cancer No with colon cancer
Saha 46 71 ns Rectum 86 74
Wiese 44 71 ns Rectum 70 70
Waters ns ns ns None 100 22
Bilchik 43 70 ns Rectum 83 33
Paramo 46 72 ns None 100 35
Wood 40 68 ns Rectum 81 61
Wood 36 64 ns None 100 11
Saha ns ns ns Rectum ns ns
Esser 55 69 ns Rectum 84 26
Bendavid ns ns ns None 100 20
Paramo 51 70 ns None 100 55
Wood 49 68 ns Rectum 78 78
Bilchik 49 68 ns Rectum 100 100
Kitagawa 71 61 ns Rectum 21 12
Feig 73 68 ns None 100 48
Broderick-Villa 50 63 ns Rectum 90 40
Tsioulias ns ns ns None 100 14
Nastro ns ns ns None 100 8
Bilchik 12 64 ns None 100 30
Cox 35 Ns ns None 100 17
Bilchik 48 70 ns Rectum 85 102
Turner 53 76 ns Rectum 86 44
Trocha 56 71 ns Rectum 88 44
Veihl 74 75 25.3 None 100 31
Levine 55 67 ns Stomach 74 37
Saha 48 71 ns Rectum 83 336
Dan 49 72 ns Rectum 88 106
Braat ns ns ns None 100 35
Bertoglio 54 ns ns Rectum 77 20
Read ns ns ns None 100 41
Patten ns 64.2 ns None 100 50
Bertagnolli 65 65 ns None 100 72
Saha 47 71 ns Rectum 91 52
Saha 48 71.3 ns Rectum 80 209
Bembenek 49 45 to 83 ns None 100 55
Codnignola 36 70.8 ns Rectum 93 52
Dahl 57 70 ns None 100 30
Bilchik 47 74 ns Rectum 73 97
Tuech ns 75.5 ns None 100 30
Saha 48 74 ns Rectum 82 408
Kelder 53 69 ns None 100 30
Thomas 50 67 c. 26.3 None 100 69
Covarelli 60 70 ns None 100 20
Kelder ns ns ns None 100 69
Bianchi 58 61 ns None 100 22
Murawa ns 61 ns Rectum 48 13
Bembenek 59 67 ns None 100 315
Sandrucci ns 73 ns Rectum 86 30
Tiffet 50 73 25 Rectum 75 49
Lim 48 67 ns None 100 120
Kusano 70 70 ns None 100 26
Quadros 36.5 56 ns Rectum 42 22
The order and format is the same as in Table 3.BMC Surgery 2008, 8:17 http://www.biomedcentral.com/1471-2482/8/17
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Table 5: Patient selection criteria along with the resulting tumor profiles in each of the studies and the mean total lymph node 
harvests. 
Lead Author Selection criteria 
employed
Tumor Size 
(cm)
T Stage 
(% of total)
T12:34 ratio Conventionally 
Node Negative 
(%)
No of lymph 
nodes resected 
(range)
T i sT 1T 2T 3T 4
Saha None ns Data not given ns 37 16 (ns)
Wiese None ns 0 14 22 53 11 36:63 41 16 (ns)
Waters None ns Data not given ns 27 12 (ns)
Bilchik Early stage primary 
only
ns 0 26 24 50 50:50 35 15 (2–28)
Paramo No distant metastatic 
disease
ns 0 12 7 81 0 7:93 29 10 (ns)
Wood Clinically localized 
primary
ns 0 19 29 44 8 48:52 47 15 (2–28)
Wood Small early stage 
cancers only
1.4 27 54 9 9 0 91:9 9 13 (2–20)
Saha None ns Data not given ns 40 20 (ns)
Esser No nodal or distant 
metastases
ns Data not given ns 19.4 15 (12–16)
Bendavid None ns Data not given ns 65 ns
Paramo No distant metastatic 
disease
ns Data not given ns 27 12 (ns)
Wood Clinically localized ns Data not given ns 26 15 (2–28)
Bilchik Clinically localized ns 0 25 23 46 6 48:52 43 15 (3–28)
Kitagawa Only if curative 
surgery
ns Data not given 29:71 43 24 (ns)
Feig None ns 7 6 23 58 6 36:64 33 13 (4–46)
Broderick-Villa No known distant 
metastases
? 6 82 0 6 24 3 4 : 6 6 4 3 8  ( 1 – 1 7 )
Tsioulias Clinically localized 
only
ns Data not given ns 21 14 (2–21)
Nastro None ns Data not given ns ns ns
Bilchik Early stage primary 
only
ns 20 46 14 20 0 80:20 21 14 (2–21)
Cox None ns 0 6 36 58 0 42:58 41 18 (4–33)
Bilchik Early stage primary 
only
3.6 14 12 17 53 5 42:58 36 14 (ns)
Turner None ns 0 12 10 75 4 22:78 52 11 (1–42)
Trocha No distant 
metastases
ns 26 12 18 42 2 56:44 38 16 (ns)
Veihl None 4.2 0 6 9 71 12 15:83 48 21 (5–40)
Levine No gross nodal 
disease
ns Data not given ns ns ns
Saha Tumor resectable & 
no metastases
ns Data not given ns 42 nsBMC Surgery 2008, 8:17 http://www.biomedcentral.com/1471-2482/8/17
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Dan None ns 17 15 13 53 3 ns 43 ns
Braat No distant 
metastases, gross 
invasion or nodal 
disease
ns 0 6 20 51 23 26:74 34 9 (1–23)
Bertoglio Stage I and II & no 
enlarged nodes only
ns Data not given ns 65 13 (6–18)
Read Surgery with curative 
intent only
ns Data not given ns 29 14 (7–45)
Patten No nodal or distant 
metastases
ns Data not given 37:63 39 14 (ns)
Bertagnolli Stage I, II and III only ns 0 29 16 46 9 35:65 67 17 (ns)
Saha None ns 19 14 11 53 4 43:57 33 12 (ns)
Saha None ns 11 10 15 51 5 34:66 41 14 (ns)
Bembenek Conventionally node 
negative patients only
ns Data not given ns 100 26 (10–59)
Codnignola No liver metastases ns 0 2 21 63 14 23:77 36 21 (6–47)
Dahl No nodal or distant 
metastases
ns Data not given 11:88 40 17 (4–35)
Bilchik Potentially curable 
cancer with no 
distant metastases 
only
3.5 (0.2–10.5) 0 17 15 65 3 32:68 29 15 (ns)
Tuech No nodal or distant 
disease
ns 0 6 9 85 0 10:90 36 20 (12–32)
Saha None ns 15 11 16 52 5 42:58 50 15 (ns)
Kelder No gross nodal or 
distant metastases
ns 0 0 23 73 4 23:77 21 14 (ns)
Thomas None ns Data not given ? 38 ns
Covarelli None ns Data not given ns 35 ns
Kelder No gross nodal or 
distant metastases
ns 0 1 20 70 9 21:79 41 11 (ns)
Bianchi No T4 or metastatic 
disease
ns 36 4.5 9 45 5 50:50 73 22 (8–38)
Murawa No gross nodal or 
distant metastases
ns 0 15 20 63 2 37:63 41 20 (3–96)
Bembenek None ns Data not given ns 69 20 (4–79)
Sandrucci Stage I or II only ns Data not given 100:0 69 9 (ns)
Tiffet Excluded if primary 
unresectable.
ns Data not given 22:78 41 18 (4–37)
Lim No gross nodal or 
distant metastases
ns 0 4 26 66 4 30:70 16 13(ns)
Kusano None ns 0 15 73 12 88:12 77 13.5 (ns)
Quadros Potential curable 
cancer, no distant 
metastases
8.3 0 0 14 54 31 14:86 46 19 (ns)
The order and format is the same as in Table 3.
Table 5: Patient selection criteria along with the resulting tumor profiles in each of the studies and the mean total lymph node 
harvests.  (Continued)BMC Surgery 2008, 8:17 http://www.biomedcentral.com/1471-2482/8/17
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Table 6: Surgeon and technical factors associated with nodal mapping, identification and pathological analysis methodology. 
Sentinel node analysis
Lead Author Surgeon 
Experience 
sought
Multicentre Laparoscopic 
resection (%)
Mapping agent 
used
Supplementay 
ex vivo 
identification
Mean/median 
No. of sentinel 
nodes (range)
Serial 
sectioning
Immunohist. 
or RT-PCR
Saha No No ns Isosulfan blue 1% No 1.6 (1 to 4) Yes No
Wiese No No 0 Isosulfan blue 1% No 1.9 (1 to 4) Yes Yes
Waters No No ns Isosulfan blue 1% No ns Yes Yes
Bilchik Yes Yes ns Isosulfan blue 1% No 2 (1 to 3) Yes Yes
Paramo No No 0 Isosulfan blue 1% No 1.4 (1 to 4) Yes Yes
Wood No No 12 Isosulfan blue 1% Yes (10%) 2 (1 to 4) Yes Yes
Wood No No 100 Isosulfan blue 1% No 2 (1 to 3) Yes Yes
Saha No Yes ns Isosulfan blue 1% No 1.7 (1 to 4) Yes Yes
Esser No No 0 Isosulfan blue 1% No 1.7 (0 to 5) No No
Bendavid No No ns Isosulfan blue 1% No 3.9 (0 to 5) Yes Yes
Paramo No No 0 Isosulfan blue 1% No 1.6 (0 to 4) Yes Yes
Wood No No ns Isosulfan blue 1% Yes (15%) 2 (1 to 4) Yes Yes
Bilchik No No 16 Isosulfan blue 1% Yes (11%) 2 (1 to 4) Yes Yes
Kitagawa No No 0 Techneticum No 3.5 (0 to 8) No No
Feig No Yes 0 Isosulfan blue 1% No 2.6 (0 to 7) No Yes
Broderick-Villa No No 0 Isosulfan blue 1% Yes (23%) 1.5 (0 to 5) Yes Yes
Tsioulias No No 100 Isosulfan blue 1% No 1.7 (1 to 3) Yes Yes
Nastro No No 0 Technetium and 
blue dye
No ns Yes Yes
Bilchik Yes No 23 Isosulfan blue 1% No 2 (1 to 3) Yes Yes
Cox No No 0 Isosulfan blue 1% Yes (58%) 6 (2 to 11) Yes Yes
Bilchik Yes No ns Isosulfan blue 1% No 1.75 (ns) Yes Yes
Turner Yes No ns Isosulfan blue 1% No 3 (ns) Yes Yes
Trocha No No 0 Technetium and 
blue dye
No 2.5 (ns) Yes Yes
Veihl No Yes 0 Isosulfan blue 1% No 2 (1 to 8) Yes Yes
Levine No No 0 Isosulfan blue 1% No 1.9 (1 to 6) No Yes
Saha Yes No ns Isosulfan blue 1% No 2.1 (ns) Yes Yes
Dan No No 0 Isosulfan and 
fluorescein
No 2.5 (ns) Yes Yes
Braat No No ns Patent Blue Yes (57%) 1.7 (1 to 4) Yes Yes
Bertoglio No No ns Vital Blue No 2.9 (1 to 3) Yes No
Read No No 0 Isosulfan blue 1% No 2 (ns) No No
Patten No No 0 Technetium and 
patent blue
No 3.5 (0 to 11) Yes Yes
Bertagnolli No Yes 0 Isosulfan blue 1% No 2.1 (ns) Yes No
Saha No No 0 Technetium and 
Isosulfan blue
No 3 (1 to 4) Yes Yes
Saha No Yes 0 Isosulfan, 
Technetium and 
fluorescein
No 2 (1 to 4) Yes Yes
Bembenek No No 0 Patent Blue No 2 (ns) Yes Yes
Codnignola No No 0 Patent Blue No 2.02 (ns) Yes Yes
Dahl No No 0 Patent Blue 
(with 
radioisotope in 
six)
Yes (6%) 2.2 (0 to 6) Yes No
Bilchik Yes Yes 15 Isosulfan blue 1% Yes (4%) 3 (ns) Yes Yes
Tuech Yes No ns Patent Blue Yes 1.5 (ns) Yes Yes
Saha Yes Yes ns Isosulfan blue 1% No 2.2 (ns) Yes yes
Kelder No No 0 Patent Blue No 2.7 (1 to 4) Yes Yes
Thomas No No 0 Isosulfan blue 1% No 2.1 (1 to 5) Yes yes
Covarelli No No 0 Technetium and 
blue dye
No 1.3 (ns) Yes Yes
Kelder Yes Yes 0 Patent Blue No 2,3 (ns) Yes Yes
Bianchi No No 100 Patent Blue Yes (5%) 2 (ns) Yes Yes
Murawa No No 0 Patent Blue No 1.6 (0 to 4) No Yes
Bembenek No Yes 7 Patent Blue No ns Yes Yes
Sandrucci No No ns Patent blue and 
technetium
No 2.2 (ns) Yes No
Tiffet No No 0 Patent blue and 
technetium
No 2.6 (ns) Yes Yes
Lim No No ns Technetium and 
Isosulfan blue
Yes 4 (ns) Yes Yes
Kusano No No 62% Indocyanine 
green
No 2.6 (0–5) No No
Quadros No No 0 Technetium and 
patent blue
Yes 3.5 (ns) Yes Yes
The order and format is the same as in Table 3.BMC Surgery 2008, 8:17 http://www.biomedcentral.com/1471-2482/8/17
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Of the sixteen studies with false negative rates above 20%,
twelve presented no critical analysis of their false negative
rates. Nor did any of these studies place any emphasis on
surgeon experience in their stated inclusion criteria. Four
studies were performed on a multicentre basis but none
explicitly ensured surgeon expertise prior to commence-
ment (in one such study the mean number of operations
per surgeon was less than three) and nine studies included
non-colonic tumors in between 10 and 26% of the cohort
size. Furthermore one study specifically commented that
tumors adherent to the retroperitoneum were included
while five had T3/4 tumors accounting for approximately
80% of their patient cohorts. Three had a mean tumor size
of greater than 4.2 cm with one concluding that its false
negatives case were associated with significantly bigger
tumor sizes (7.2 cm in the false negative cases versus 5.2
cm mean size overall). One additional study also found a
strong trend in favor of an association between false neg-
ative rate and larger tumor sizes (4.5 cm v 3.5 cm, p =
0.09). Two studies had a mean number of resected lymph
nodes of eight and nine respectively while at least twelve
studies included some patients with less than ten nodes in
their resected specimens (eight including some with five
or less nodes examined). Two others presented no mean
data on this subject and three presented no range. Four
did not serially section the sentinel node while six did not
employ immunohistochemistry or RT-PCR.
With respect to the fifteen publications with false negative
rates between 10 and 20%, only three studies included
specific analysis of their rates. Of the fifteen, two were
multicentric trials and both sought to ensure surgical
expertise and had false negative rates each of 11 and 12%.
Nine studies included rectal cancers in their cohorts (in
between 9% and 74% of their cohorts). Four studies had
no explicit exclusion criteria while six sought only to
exclude distant disease deposits. No study provided any
data on patient BMI. Only one study specifically excluded
T4 disease. Eight had a significant (>60%) T3/4 prepon-
derance (being >70%). The mean number of resected
lymph nodes was greater than ten in fourteen. Four stud-
ies included patients with less than this number while the
one presented no data regarding the range. Two studies
did not employ serial sectioning of the identified sentinel
nodes and two did not utilize immunohistochemical or
RT-PCR methods of examination.
Discussion
Sufficient lymph basin resection is an oncologic sine non
qua of operation with curative intent for solid organ
malignancies as nodal status remains the primary portent
of prognosis and adjuvant therapy prescription. For colon
cancer, staging propriety by convention demands that this
equate to en bloc resection of the entire mesenteric lym-
phatic delta. While the manner of performance of stand-
ard resectional operation for colon cancer by laparoscopy
or laparotomy means that the extent of access is already
determined (and so supplementing bowel resection with
full mesenteric resection is readily facilitated) this is not
for case for endoscopic resectional techniques. Therefore
these techniques are currently limited to the address of
benign lesions or neoplastic disease with minimum like-
lihood of lymphatic dissemination. A minimally invasive
means of reliably confirming the lymph node status could
greatly enhance the oncological propriety of these
approaches and extend their indications towards their
actual technical capacity. While it is clear that sentinel
node biopsy is not indicated to minimize the extent of
therapeutic lymphadenectomy in colon cancer (i.e. the
resection of nodes containing tumor deposits), it could
theoretically have a role in helping select those with truly
early stage disease for endoscopic resection.
Furthermore, although it is often considered that adjoin-
ing mesenteric lymph node dissection to the intestinal
resection impacts little on the patient undergoing conven-
tional oncological operation for colon cancer [100-103],
this assumption does not necessarily stand up to close
scrutiny. The high-tie of the arterial inflow arcade neces-
sary to adequately perform mesenteric nodal dissection
however segues wider longitudinal intestinal margins
than would otherwise be necessary for local clearance pur-
poses alone. The negative impact of wide dissection and
resection may include post-operative bowel dysfunction,
nerve plexus praxia or adjacent organ injury [104-106].
Therefore, tacit knowledge, as well as some prior clinical
investigation [107-109], would suggest that minimizing
the extent of mesenteric dissection could pay dividends
for the patient even if standard surgical access is
employed. These considerations have however been lost
amid the concerns regarding the efficacy of lymphatic
mapping in this disease and the current emphasis on
ensuring adequate staging by resection of considerable
'minimum' numbers of lymph nodes [110-112].
The focus of sentinel node biopsy in colon cancer has
therefore been on upstaging conventionally node negative
patients after conventional radical operation[113]. This
means that false-negative sentinel nodes do not impose
any negative effect on the patient but also has conferred a
priori license to investigators to modify the technique and
broaden the patient cohort. To propose that it could be
used a means of predicting a negative basin and obviating
mesenteric dissection places great emphasis on ensuring
that the technique's rationale in colon cancer is biologi-
cally sound and that methodological discrepancies are
eliminated. However the literature base to date contains
multiple un-standardized variables and so assessment of
the true utility of lymphatic mapping when applied selec-
tively to early stage disease is considerably confounded.BMC Surgery 2008, 8:17 http://www.biomedcentral.com/1471-2482/8/17
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Spread of (a) Detection rates and (b) False Negative Rates among the studies of in vivo sentinel node mapping in colon cancer  included in this review Figure 2
Spread of (a) Detection rates and (b) False Negative Rates among the studies of in vivo sentinel node mapping 
in colon cancer included in this review. In the figures, studies arising from either of the two centers with the most publi-
cations (ie The John Wayne Cancer Institute, California and the McLaren Reginal Cancer Centre, Michgan) on the topic are 
indicated separately to minimize any visual bias resulting from their inclusion. The remaining studies are divided into multi-
center studies and all others.BMC Surgery 2008, 8:17 http://www.biomedcentral.com/1471-2482/8/17
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The high accuracy rates in some studies do at least suggest
that its concept is biologically tenable (indeed of those
centers that have published multiple series, four conclude
strongly in favor of the reliability of the technique) and
that methodological variability may underlie the discord-
ant results (as they do for the same technique in malig-
nancies at different sites). However, this heterogeneity
also confounds any attempt at meta-analysis to selectively
extract data regarding the reliability of sentinel node
biopsy selectively in early stage cancer. A similar conclu-
sion was also reached by another group performing a
detailed statistical systematic review of the literature from
another perspective[114]. Although their review contains
significant differences in study inclusion and exclusion
criteria to ours, it is interesting that they nonetheless con-
cluded that the technique had a 9% median risk of a false
negative result in comparison to an 8.4% median risk for
the technique in breast cancer. However, the general ten-
dency to pool results in the reporting of studies frustrated
their attempt to relate T-stage to sensitivity.
The first evident confounder to obtaining clarity regarding
the accuracy of the technique is the number of publica-
tions emanating from single centers. Although it seems
likely that these seven centers (who together have contrib-
uted over half of the published evidence base) have over-
lapped their patient cohorts at least to some extent in
successive publications, the exact proportions is rarely
explicitly declared. Equally however it cannot be assumed
that these studies entirely overlapped their experiences
and so to ensure fairness and transparency every study
meeting the inclusion exclusion is included in this study
with those coming from the same center being flagged in
the Tables. The next main obstacle within each publica-
tion complicating deliberation of the technique's applica-
bility for early stage colon cancer is the marked
contamination of rectal cancers throughout the evidence
base. The consequences of doing so without presentation
of complete subgroup analyses gives an artificial impres-
sion of reduced feasibility and accuracy rates overall
because lymphatic mapping is clearly more arduous and
less reliable in this site[115]. Furthermore, specific
account of tumor size and mural penetration in colon
cancer is too often lacking for any firm conclusions to be
made regarding the efficacy of selectively mapping early
stage disease. The main inclusion criterion to date is pri-
marily the requirement for operation for symptomatic
colon cancer despite the fact that the disease tends to
present late (often at stage when curative surgery is not
possible and adjuvant treatment is already indicated
regardless of the nodal status). An elongated diameter of
the cancer may also mean that different segments of the
tumor map to different nodes as watershed areas are
crossed. Furthermore, direct spread through the bowel
wall may compress and alter the original lymphatic flow
and so cause the mapping agent to deviate away from the
Table 7: Tabulated summary of the specific analyses of failed or false negative analysis where such has been explicitly contained within 
the publication.
Authors Year Comment
Bendavid [56] 2002 The one false negative case occurred in a patient with liver metastases.
Also 'evidently metastatic nodes' did not receive colourant
Paramo [57] 2002 No specific analysis presented.
Wood [58] 2002 All five false negatives occurred in T3 or T4 tumors (in one case the only positive non-sentinel node was involved by 
direct extension). Three occurred in 1st 30 cases
Bilchik [59] 2002 All five false negatives occurred in T3 or T4 tumors. Three occurred in the first fifty cases.
Kitagawa [60] 2002 Four false negative cases were advanced T3 and/or had massive lymph node metastases
Feig [61] 2002 Also 'several patients' (of ten) classified as false negative had 'palpable lymph nodes'
Broderick-Villa [62] 2002 Learning curve strongly associated with false negative rate (67% in first half, 32% in second half). No significant 
association with T-stage, LN involvement or tumor diameter > or < 4 cm
Veihl [70] 2003 Amount of dye relative to tumor size was an important predictor of identification of node. False negative more 
common in cases with larger nodes (4.5 cm v 3.4 cm, p = 0.09)
Bilchik [83] 2006 Of the six false negatives, four were attributable to tumor obliteration of the lymphatic channels
Saha [85] 2006 95% of patients with skip metastases were T3 or T4
Thomas [87] 2006 Two patients with liver metastases along with two others with gross mesenteric disease had false positive sentinel 
nodes. No relationship between BMI and disease
Kelder [89] 2006 In one of the two false negatives, the non-SLNs were involved by extra-nodal tumor invasion
Bembenek [92] 2007 Significant association with learning curve/center experience, BMI (cut-off level being 22 patients and a BMI of 25 
respectively) & LVI. No significant association between detection and T stage, age, sex, vascular invasion, no of nodes, 
total no of nodes.
Sandrucci [93] 2007 'Skip metastases' were all correlated with 'T2 lesions with massive lymphatic involvement'
Tiffet [94] 2007 Three of 12 false negatives were in patients with direct tumor involvement of adjacent non-sentinel epicolic nodes 
while four were in N2 patients. False negative rate markedly lower in the subgroup with T1 and T2 tumors only. and 
in those with BMI < 30 kg/m2BMC Surgery 2008, 8:17 http://www.biomedcentral.com/1471-2482/8/17
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original first order draining nodes. Extensive nodal
involvement, including total destruction of the nodes by
metastases, may also compromise the identification of
true sentinel nodes[22,116]. Such concerns have been
confirmed in the analyses presented here as well as in ex
vivo experiences of mapping colon cancer and indeed in
other tumors [117-119].
Surgeon expertise and experience has already been deter-
mined a major feature for lymphatic mapping in breast
cancer[120] and seems likely to also be one for colonic
mapping (a point made clear in one study attempting ex
vivo biopsy that found many of their failed mapping were
associated with intraluminal dye injection)[39]. The rela-
tionship between low detection rate and higher false neg-
ative rate is a likely related phenomenon while lack of
technical proficiency may in addition compound any
technical difficulties associated with adverse patient fac-
tors (such as BMI or previous laparotomy) to further
undermine the performance of the technique. A specific
learning curve can also certainly be expected if the surgeon
looks for the nodes intraoperatively. However the lack of
specific inclusion criteria for this seems to suggest that
many of the studies published to date are in fact reflec-
tions of expertise acquirement rather than reports of tech-
nique reliability. The timing of the vital blue dye injection
prior to resection may also be a crucial issue. A prolonged
latency in identifying the node (depending on the intra-
operative situation) may allow overflowing of the dye and
potentially complete decoloration of the first stained
node. Also the discrepancy in standardizing nodal analy-
sis between the reports is concerning as standard assess-
ment based on hematoxylin and eosin staining of one
level of a paraffin-embedded block reportedly can miss as
many as 33% of metastases[121]. While micrometastatic
disease may of itself be of considerable clinical impor-
tance [115], these cells in sentinel nodes may also confer
significance by their prediction of the presence of non-
sentinel nodal metastases. Finally the numbers within the
nodal harvest rates of many studies raises serious concerns
over quality assurance utilized given that this aspect is of
utmost importance when a novel technique is compared
to established practice.
Certain groups have however clearly managed to over-
come confounding factors of the technique and consist-
ently obtain negative predictive values of similar quality
to those that currently justify conservative resection fields
in other specialties. It is perhaps no surprise that these
investigators tend to fastidiously analysis their false nega-
tive results as did the pioneers of the technique in breast
cancer and melanoma. On the other hand, other authori-
ties have not hesitated to declare the technique in colon
cancer either invalid or of dubious clinical value[40,122]
on the basis of their own experience and perception of the
evidence base. Most of the latter group did not however
present data detailing their efforts to examine the poten-
tial biological reasons behind their results. As much there-
fore as it is clear that certain proponents in both single
centre and multicentre trials can perform sentinel node
biopsy with high accuracy for colonic malignancy, it is
equally clear that others cannot. The fact that advanced
endoscopic resection is at present only wrought in
supraspecialized centers may mean however that only
such selected, expert departments need attempt to investi-
gate, validate and standardize the performance of sentinel
node biopsy to accompany it. Also, the need for high
detection and accuracy rates implicit if the results were
going to impinge on patient care could drive efforts to
develop methods to improve the yield of lymphatic map-
ping by use of additional or alternative dyes (perhaps flu-
orescent markers[73,123] or radioisotopes[69,78]) as
have been used for other cancers [124-126].
The general tendency of a relationship between advancing
stage an increased likelihood of metastases being present
in non-sentinel nodes also supports the basic contention
that lymphatic mapping in colon cancer may be particu-
larly efficacious in germinal cancers – a perspective made
particularly compelling by the inherent suitability of early
stage disease for truly minimally invasive resective tech-
niques. The lesions that could be resected by endoscopic
means are by definition smaller and therefore likely con-
fined to a single lymphatic delta. Furthermore T3 or T4
disease identifiable by staging is not feasibly resected
endoscopically and so the tumor stages with the highest
frequency of being node-positive are excluded. The fact
that 20–40% of patients with T3/4 lesions but without
demonstrable lymph node metastases actually die of their
disease also supports exclusion of these patients from
non-radical operation. De facto confinement of the
patient cohort to T1 and T2 stage disease (perhaps by
including adjunctive staging measures such as endoscopic
ultrasound[127]) may therefore obviate some of the main
confounders of lymphatic mapping and potentially allow
proffering of localized tumor resection as definitive sur-
gery. However the lack of specific study or discriminating
subgroup analysis by T-stage means that this aspect of
lymphatic mapping in colon cancer has yet to be defini-
tively explored and so this remains speculative.
If sentinel node biopsy is ever to be used as means to alle-
viate mesenteric resection in cases that are truly node neg-
ative, consideration must be given to the cases where the
sentinel node is positive or indeed falsely negative. In the
former case, subsequent radical lymphadenectomy
should still be performed. Ideally therefore the sentinel
node analysis should be performed intraoperatively to
allow direct progress to the definitive excisional surgery
(whether of the primary alone or of the traditionalBMC Surgery 2008, 8:17 http://www.biomedcentral.com/1471-2482/8/17
Page 16 of 20
(page number not for citation purposes)
extended operation). Considerable precedent exists for
such analysis in breast cancer [128-131] and it is even pos-
sible that additional innovative technology may allow for
in situ virtual biopsy of the salient nodes[132,133]. In the
situation that the sentinel node is falsely negative, suspi-
cious features present in the resected specimen may
encourage revisional surgery in some cases. Although re-
intervention after a previous laparotomy may be difficult,
the risk of added morbidity because of a prior minimally
invasive 'cherry-picking' of sentinel nodes is likely to be
less. However any true consideration of the risk involved
needs balancing with an accurate measure of the potential
benefit of avoiding mesenteric resection. The conse-
quence of missed positive lymph nodes is mainly one of
potential understaging and hence depriving the patient of
systemic chemotherapy. However it should also be real-
ized the added benefit of chemotherapy over standard
surgery for T1 and T2 lesions is low and perhaps that the
clinical significance of minimal nodal disease in these
patients is lower than that of more advanced T-stage (as is
the case for early gastric cancer[134])[135,136]. The
actual clinical risk of detriment due to mesenteric lym-
phadenopathy per se is also low[85]. It is worth however
here emphasizing again that these deliberations only
apply to colon cancer and not its counterpart in the rec-
tum. The anatomic characteristics of the mesorectum
(namely its bulk, extraperitoneal situation and lack of a
serosal layer) mitigate against selective sentinel node
biopsy in isolation for rectal cancer however as does the
fact that transgression of its planes may complicate any
subsequent total mesorectal resection in cases of nodal
positivity and so impact upon the potential for curative
resection. Finally the consequences of missed nodal dis-
ease in the pelvis and, therefore the occurrence of pelvic
recurrence, may be catastrophic for the patient.
Conclusion
Sentinel node mapping could never substitute for a prop-
erly performed oncologic colorectal resection when this is
indicated. The concept however that lymphatic mapping
may have sufficient capability to provide the oncological
proprietary for the curative surgery for early stage cancers
without en bloc mesenteric resection seems biologically
plausible but cannot yet be definitively judged given the
lack of clarity and consistency in the literature to date.
Specific study of the technique in those early stage tumors
likely to be selected for endoscopic resection is clearly
therefore essential before this approach can be considered
in clinical practice.
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